World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
102
Citations
64114
World Ranking
7495
National Ranking
288

Christian U. Blank publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Christian U. Blank sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 456 publications — 50th percentile

50% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Christian U. Blank D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Christian U. Blank sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 102 D-Index — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Christian U. Blank is affiliated with the Antoni van Leeuwenhoek Hospital in the Netherlands and has contributed extensively to research primarily within the fields of Medicine and Biochemistry, Genetics, and Molecular Biology. Their work spans several subfields including Oncology, Molecular Biology, Immunology, Pulmonary and Respiratory Medicine, and Cancer Research.

Their research focuses on key topics such as Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, Immunotherapy and Immune Responses, Brain Metastases and Treatment, and Ocular Oncology and Treatments.

Christian U. Blank's frequent co-authors include:

  • John B.A.G. Haanen
  • Georgina V. Long
  • Ellen Kapiteijn
  • Karijn P.M. Suijkerbuijk
  • Geke A.P. Hospers

Their publications are regularly featured in venues such as:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • Nature Medicine
  • Journal for ImmunoTherapy of Cancer

Some of the recent papers by Christian U. Blank include:

  • "B cells and tertiary lymphoid structures promote immunotherapy response," 2020, Nature
  • "The human tumor microbiome is composed of tumor type-specific intracellular bacteria," 2020, Science
  • "Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma," 2022, New England Journal of Medicine
  • "Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo," 2020, JAMA Oncology
  • "Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)," 2021, Nature Medicine

The breadth and focus of their work illustrate a sustained engagement with both clinical and molecular aspects of cancer research and immunotherapy, especially concerning melanoma and immune system interactions.

Best Publications

  • Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Caroline Robert;Caroline Robert;Caroline Robert;Jacob Schachter;Georgina V. Long;Ana Arance

  • Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

    Axel Hauschild;Jean Jacques Grob;Lev V. Demidov;Thomas Jouary

  • Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

    Eliezer M. Van Allen;Eliezer M. Van Allen;Diana Miao;Diana Miao;Bastian Schilling;Sachet A. Shukla;Sachet A. Shukla

  • B cells and tertiary lymphoid structures promote immunotherapy response

    Beth A. Helmink;Sangeetha M. Reddy;Jianjun Gao;Shaojun Zhang

  • LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells.

    Almut Brand;Katrin Singer;Gudrun E. Koehl;Marlene Kolitzus

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • The human tumor microbiome is composed of tumor type–specific intracellular bacteria

    Deborah Nejman;Ilana Livyatan;Garold Fuks;Nancy Gavert

  • Defining ‘T cell exhaustion’

    Christian U Blank;W Nicholas Haining;Werner Held;Patrick G Hogan;Patrick G Hogan

  • Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

    Jacob Schachter;Antoni Ribas;Georgina V. Long;Ana Arance

  • Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

    Hanjie Li;Anne M. van der Leun;Ido Yofe;Yaniv Lubling

  • Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

    David Liu;David Liu;Bastian Schilling;Bastian Schilling;Derek Liu;Derek Liu;Antje Sucker

  • PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

    Christian Blank;Ian Elliott Brown;Amy C. Peterson;Mike Spiotto

  • Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

    Caroline Robert;Antoni Ribas;Jacob Schachter;Ana Arance

  • Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

    Chong Sun;Liqin Wang;Sidong Huang;Guus J. J. E. Heynen

  • Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.

    Christian Blank;Thomas F. Gajewski;Andreas Mackensen

  • The “cancer immunogram”

    Christian U. Blank;John B. Haanen;Antoni Ribas;Ton N. Schumacher

  • MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

    Paolo A. Ascierto;Dirk Schadendorf;Carola Berking;Sanjiv S. Agarwala

  • Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

    Leonie Voorwerk;Maarten Slagter;Hugo M. Horlings;Karolina Sikorska

  • Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

    Christian U. Blank;Elisa A. Rozeman;Lorenzo F. Fanchi;Karolina Sikorska

Frequent Co-Authors

John B. A. G. Haanen
John B. A. G. Haanen Antoni van Leeuwenhoek Hospital
Georgina V. Long
Georgina V. Long University of Sydney
Ton N. M. Schumacher
Ton N. M. Schumacher Antoni van Leeuwenhoek Hospital
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Caroline Robert
Caroline Robert University of Paris-Saclay
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Matteo S. Carlino
Matteo S. Carlino University of Sydney
Alexander M. Menzies
Alexander M. Menzies University of Sydney
Richard A. Scolyer
Richard A. Scolyer Royal Prince Alfred Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering studying Medicine in the USA, you may also be interested in flexible online nursing programs that support diverse career goals. These options can help you gain qualifications without sacrificing work or personal commitments.

Many working nurses look for online rn to bsn programs without clinicals, which let you advance your education conveniently while avoiding additional clinical requirements. For those aiming for advanced practice roles, pursuing a 1 year dnp program online is a fast-track option to earn a terminal nursing degree quickly.

If you value flexibility and manageable coursework, exploring easiest online dnp programs could help meet your career ambitions with less stress. Alternatively, those who want to start working in healthcare sooner might consider a 6 month lpn program for rapid entry into the field.

Each of these pathways has unique benefits and challenges, so it’s important to research which program best matches your educational background and career objectives.

Best Scientists Citing Christian U. Blank

Trending Scientists